Form 8-K - Current report:
SEC Accession No. 0001193125-26-197489
Filing Date
2026-04-30
Accepted
2026-04-30 16:30:29
Documents
13
Period of Report
2026-04-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d308328d8k.htm   iXBRL 8-K 34166
2 EX-1.1 d308328dex11.htm EX-1.1 187173
3 EX-5.1 d308328dex51.htm EX-5.1 6943
  Complete submission text file 0001193125-26-197489.txt   401031

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA ntla-20260427.xsd EX-101.SCH 3175
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20260427_lab.xml EX-101.LAB 17993
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20260427_pre.xml EX-101.PRE 11258
16 EXTRACTED XBRL INSTANCE DOCUMENT d308328d8k_htm.xml XML 3630
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

EIN.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37766 | Film No.: 26926121
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)